Back to News
Market Impact: 0.2
Does Cullinan Therapeutics (CGEM) Have the Potential to Rally 129.63% as Wall Street Analysts Expect?
Source: zacks.com
Analyst InsightsAnalyst EstimatesHealthcare & Biotech
Analysts’ mean price target for Cullinan Therapeutics (CGEM) implies 129.6% upside, but the article cautions that price targets have not proved reasonably effective. It says strong analyst agreement in raising earnings estimates may indicate upside, without providing an estimate magnitude or timeframe.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
CGEM0.30
More News
- Alphabet just had its worst day as a public company. BofA now values Google search at a lower multiple than fossil fuel stocks
- Intel plunges on a major guidance miss. What went wrong — and how to proceed
- FedEx Freight delivers a much-needed quarterly beat. Where we stand on shares now
- We're cutting our Amazon price target after a tough quarter. But it isn't all bad
- We're raising our price target on Eli Lilly as the obesity-drug boom rolls on
- ATEC Q3 2026 slides show profitability surge despite execution gaps